Co-Diagnostics Announces Reverse Stock Split
Key Highlights
- ➤1-for-25 reverse split effective November 24, 2026
- ➤CODX targets Nasdaq $1 minimum bid compliance
- ➤13,044,465 shares expected to become approximately 521,779
- ➤Reverse split preserves authorized shares for potential equity financings
SALT LAKE CITY, Nov. 19, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Diagnostics" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has filed Articles of Amendment to its Articles of Incorporation (the "Amendment") to effect a reverse stock split of its issued and outstanding common stock at a ratio of 1-for-25 shares (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. ET on Tuesday, November 24, 2026. The Company's common stock will continue to trade on The Nasdaq Capital Market under the symbol "CODX" and will begin trading on a split-adjusted basis when the market opens on Tuesday, November 24, 2026. The Reverse Stock Split is intended to enable the Company to maintain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, and to maintain sufficient authorized shares available for issuance to allow the Company to conduct equity financings as needed. The new CUSIP number for the Company's common stock following the Reverse Stock Split will be 189763 303.
Get started
Create a free account to read the full story.
